Efficacy and Safty of Camrelizumab Plus S-1 Maintenance After First-line Induction Chemotherapy for GC
Conditions
Brief summary
In this study, We investigated the efficacy and safty of camrelizumab combined with S-1 maintenance after first-line induction chemotherapy for GC. Patients without progressive disease after 4-6 weeks of first-line chemotherapy with SOX will be treated with camrelizumab combined with S-1.
Interventions
DRUGCamrelizumab+S-1
Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks.
Sponsors
Peking Union Medical College Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female subjects aged from 18 to 75 years old; 2. Subjects with histologically confirmed unresectable locally advanced or metastatic adenocarcinoma of the stomach or gastro-esophageal junction (GEJ); 3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at trial entry; 4. Disease must be measurable by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1); 5. Estimated life expectancy of more than 3 months; 6. Adequate haematological, hepatic and renal functions defined by the protocol; 7. Negative blood pregnancy test at Screening for women of childbearing potential; Highly effective contraception for both male and female subjects if the risk of conception exists;
Exclusion criteria
1. Concurrent anticancer treatment such as chemotherapy, radiotherapy, targeted or immunotherapy; 2. Tumor shown to be human epidermal growth factor 2 plus (HER2+); 3. Previous malignant disease (other than gastric cancer) within the last 5 years with the exception of basal or squamous cell carcinoma of the skin or carcinoma in situ (bladder, cervical, colorectal, breast); 4. Severe infection (e.g. need for intravenous antibiotics, antifungal or antiviral drugs) occurred within 4 weeks before the first administration, or fever (\>38.5%) of unknown reason occurred during the screening period/before the first administration； 5. Any active autoimmune disease or history of autoimmune disease (such as interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (can be included after hormone replacement therapy)); The subjects with childhood asthma who had been completely relieved and did not need any intervention or vitiligo in adulthood could be included, but the subjects who needed bronchodilator for medical intervention could not be included; 6. Patients with congenital or acquired immune deficiency, such as human immunodeficiency virus (HIV) infection, active hepatitis B (HBV DNA ≥ 500 IU / ml), hepatitis C (HCV antibody positive and HCV-RNA higher than the detection limit of the analytical method), or co infection of hepatitis B and hepatitis C; 7. Used immunosuppressive drugs within 14 days before the first dose of study drug, excluding nasal and inhaled corticosteroids or physiological doses of systemic corticosteroids; 8. Accination with live or live/attenuated viruses within 28 days of the first dose of camrelizumab and while on trial is prohibited except for administration of inactivated vaccines; 9. History of uncontrolled intercurrent illness including hypertension, active infection, diabetes or cardiac diseases or symptoms; 10. Prior organ transplantation, including allogeneic stem-cell transplantation； Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival (PFS) | From the start of randomization to a minimum of 42 months | PFS is defined as time (in months) from date of randomization to the date of the first documentation of objective progressive disease (PD) or death due to any cause in the absence of documented PD (whichever occurs first). PFS will be determined according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) based on investigator response assessment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0 | From the the first dose of study drug administration up to 28 days after the last dose of study drug administration, assessed up to 3.5 years | TEAEs will be defined as the adverse events (AEs) that occur between first dose of study drug administration and 28 days after the last dose of study drug administration that were absent before treatment or that worsened relative to pretreatment state. |
| Objective Response Rate（ORR） | From the start of randomization to a minimum of 42 months | Assess ORR, defined as Investigator-assessed CR + PR, per RECIST 1.1. |
| Disease Control Rate (DCR) | Time Frame: From the start of randomization to a minimum of 42 months | Percentage of patients with CR/PR/SD in the number of patients that whose tumour can be evaluated. |
| Overall Survival（OS） | From the start of randomization to a minimum of 42 months | OS is defined as the time (in months) from randomization to the date of death, regardless of the actual cause of the subject's death. |
Countries
China
Outcome results
None listed